^
+ Follow DR. PETER S Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 636431
                    [Title] => Hearty news from MSD
                    [Summary] => 

A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events  defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure  by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).

[DatePublished] => 2010-12-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) ) )
DR. PETER S
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 636431
                    [Title] => Hearty news from MSD
                    [Summary] => 

A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events  defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure  by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).

[DatePublished] => 2010-12-07 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Health And Family [SectionUrl] => health-and-family [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with